A Jordanian Multidisciplinary Consensus Statement on Chronic Kidney Disease Screening, Diagnosis, and Management

Mohammad Ghnaimat; Muneer Ali Abu Alsamen; Mohamed Omar Abu Hijleh; Nadim Jarrah; Munther Al-Momani; Hiba Barghouthi; Abdelkarim Khawaldeh; Taroub Khoury; Riyad Said; Mazen Matalka

doi:doi:10.11648/j.jfmhc.20230903.13

Research Article |

A Jordanian Multidisciplinary Consensus Statement on Chronic Kidney Disease Screening, Diagnosis, and Management

Mohammad Ghnaimat^*, Muneer Ali Abu Alsamen, Mohamed Omar Abu Hijleh, Nadim Jarrah, Munther Al-Momani, Hiba Barghouthi, Abdelkarim Khawaldeh, Taroub Khoury, Riyad Said, Mazen Matalka

Published in Journal of Family Medicine and Health Care (Volume 9, Issue 3)

Received: 25 September 2023 Accepted: 16 October 2023 Published: 28 October 2023

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Background: Chronic kidney disease (CKD) is a global public health concern, affecting millions of people worldwide and Jordan is no exception to this growing problem. CKD can be prevented or delayed through effective primary healthcare practices. However, lack of awareness among both the general population and healthcare providers (HCPs) contributes to delayed diagnosis and suboptimal management of CKD. Aims: The aims of the expert panel were to raise awareness and provide a multidisciplinary consensus approach to screening, diagnosis, and management of CKD, including identifying and controlling risk factors associated with this chronic condition. In addition, the aim was to develop treatment recommendations and algorithms to HCPs to ease the decision-making process and standardize management protocols. Methods: The multidisciplinary panel of experts from different specialties representing several medical societies met to discuss and review the challenges and barriers of CKD in Jordan. The experts also reviewed the relevant publications associated with CKD, including the outcome data trials and the international clinical practice guidelines on CKD. The multidisciplinary panel developed a comprehensive understanding of the current state of CKD in Jordan and the measures being taken to address it. Results: The multidisciplinary team of experts developed a consensus statement that is tailored to the local situation in Jordan. The panel provided standard recommendations and algorithms, addressing screening, diagnosis, referrals, and treatment of CKD. Conclusion: Early screening and interventional programs are crucial to delaying the progression nature of CKD and reducing its complications. Future follow-up is important to measure the impact of these recommendations and educational programs to HCPs on CKD detection and management and improving patients’ outcomes.

Published in	Journal of Family Medicine and Health Care (Volume 9, Issue 3)
DOI	10.11648/j.jfmhc.20230903.13
Page(s)	54-63
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2024. Published by Science Publishing Group

Keywords

Chronic Kidney Disease, Screening, Diagnosis, Management, Consensus, Multidisciplinary, Jordan

References

[1]	GBD Mortality Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015; 385: 117–171.
[2]	Rhee CM, Kovesdy CP. Epidemiology: spotlight on CKD deaths-increasing mortality worldwide. Nat Rev Nephrol. 2015; 11: 199–200.
[3]	Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl (2011). 2022 Apr; 12 (1): 7-11. doi: 10.1016/j.kisu.2021.11.003. Epub 2022 Mar 18.
[4]	Foreman KJ, Marquez N, Dolgert A, et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories. Lancet. 2018; 392: 2052–2090.
[5]	Hill NR, Fatoba ST, Oke JL, et al. Global prevalence of chronic kidney disease–a systematic review and meta-analysis. PLoS ONE. 2016; 11 (7): e0158765.
[6]	Chen TK, Knicely DH, Grams ME. Chronic Kidney Disease Diagnosis and Management: A Review. JAMA. 2019 Oct 1; 322 (13): 1294-1304. doi: 10.1001/jama.2019.14745.
[7]	Khalil AA, Abed MA, Ahmad M, Mansour AH. Under-diagnosed chronic kidney disease in Jordanian adults: prevalence and correlates. J Ren Care. 2018 Mar; 44 (1): 12-18. doi: 10.1111/jorc.12214. Epub 2017 Sep 7.
[8]	Farah RI, Al-Sabbagh MQ, Momani MS, et al. Diabetic kidney disease in patients with type 2 diabetes mellitus: a cross-sectional study. BMC Nephrol. 2021 Jun 16; 22 (1): 223. doi: 10.1186/s12882-021-02429-4.
[9]	National Registry of End Stage Renal Disease. 13th Annual Report 2020. https://www.moh.gov.jo/ebv4.0/root_storage/ar/eb_list_page/kidney_report_2020_finale.pdf. Accessed 1 June, 2023.
[10]	Center for Disease Control and prevention. Jordan Factsheet. https://www.cdc.gov/globalhealth/countries/jordan/default.htm. Accessed 1 June, 2023.
[11]	Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013; 3 (1): 1-150.
[12]	Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2022; 102: S1-S127.
[13]	de Boer IH, Khunti K, Sadusky T, Tuttle KR, Neumiller JJ, Rhee CM, Rosas SE, Rossing P, Bakris G. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2022 Nov; 102 (5): 974-989. doi: 10.1016/j.kint.2022.08.012. Epub 2022 Oct 3 PMID: 36202661.
[14]	El Sayed NA, Aleppo G, Aroda VR, et al. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes — 2023. Diabetes Care 2023; 46 (Supplement_1): S191–S202.
[15]	Cheung AK, Chang TI, Cushman WC, et al. Executive summary of the KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int. 2021 Mar; 99 (3): 559-569. doi: 10.1016/j.kint.2020.10.026.
[16]	James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014; 311 (5): 507-520.
[17]	Whelton PK, Carey RM, Aronow WS, et al. ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018; 71 (19): e127-e248.
[18]	Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993 Nov 11; 329 (20): 1456-62. doi: 10.1056/NEJM199311113292004.
[19]	Parving H.-H., Lehnert H., Br¨ochner-Mortensen J, Gomis R, Andersen S, and Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 Diabetes. N Engl J Med., vol. 345, no. 12, pp. 870–878, 2001.
[20]	Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. vol. 345, no. 12, pp. 851–860, 2001.
[21]	Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med., vol. 345, no. 12, pp. 861–869, 2001.
[22]	Ruggenenti P, Perna A, Loriga G, et al. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomized controlled trial. The Lancet, vol. 365, no. 9463, pp. 939–946, 2005.
[23]	Hou FF, Zhang X, Zhang GH, et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency,” New England Journal of Medicine, vol. 354, no. 2, pp. 131–140, 2006.
[24]	Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators,” Lancet, vol. 355, no. 9200, pp. 253–259, 2000.
[25]	Mann JFE, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008; 372 (9638): 547-553.
[26]	Kidney Disease: Improving Global Outcomes (KDIGO) Lipid Work Group. KDIGO clinical practice guideline for lipid management in chronic kidney disease. Kidney Int Suppl. 2013; 3: 259-305.
[27]	Sarnak MJ, Bloom R, Muntner P, et al. KDOQI US commentary on the 2013 KDIGO Clinical Practice Guideline for Lipid Management in CKD. Am J Kidney Dis. 2015; 65 (3): 354-366.
[28]	Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 2019 Sep 10; 140 (11): e563-e595. doi: 10.1161/CIR.0000000000000677.
[29]	de Boer IH, Khunti K, Sadusky T, Tuttle KR, Neumiller JJ, Rhee CM, Rosas SE, Rossing P, Bakris G. Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care. 2022 Dec 1; 45 (12): 3075-3090. doi: 10.2337/dci22-0027.
[30]	Rossing P, Caramori ML, Chan JCN, et al. Executive summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: an update based on rapidly emerging new evidence. Kidney Int. 2022 Nov; 102 (5): 990-999. doi: 10.1016/j.kint.2022.06.013.
[31]	Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, et al; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015; 373: 2117–2128. doi: 10.1056/NEJMoa1504720.
[32]	Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR; CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017; 377: 644–657. doi: 10.1056/NEJMoa1611925.
[33]	Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, et al; DECLARE–TIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019; 380: 347–357. doi: 10.1056/NEJMoa1812389.
[34]	Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masiukiewicz U, Charbonnel B, Frederich R, Gallo S, Cosentino F, et al; VERTIS CV Investigators. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med. 2020; 383: 1425–1435. doi: 10.1056/NEJMoa2004967.
[35]	Bhatt DL, Szarek M, Pitt B, Cannon CP, Leiter LA, McGuire DK, Lewis JB, Riddle MC, Inzucchi SE, Kosiborod MN, et al; SCORED Investigators. Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med. 2021; 384: 129– 39. doi: 10.1056/NEJMoa2030186.
[36]	Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, et al; CREDENCE Trial Investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019; 380: 2295–2306. doi: 10.1056/NEJMoa1811744.
[37]	Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, Mann JFE, McMurray JJV, Lindberg M, Rossing P, et al; DAPA-CKD Trial Committees and Investigators. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020; 383: 1436–1446. doi: 10.1056/NEJMoa2024816.
[38]	Herrington WG, Staplin N, Wanner C, et al; EMPA-KIDNEY Collaborative Group. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2022. [PMID: 36331190] doi: 10.1056/NEJMoa2204233.
[39]	Shlipak MG, Tummalapalli SL, Boulware LE, et al. The case for early identification and intervention of chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 2021 Jan; 99 (1): 34-47. doi: 10.1016/j.kint.2020.10.012.
[40]	Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber LV, Lawson FC, Ping L, Wei X, Lewis EF, et al; ELIXA Investigators. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015; 373: 2247–2257. doi: 10.1056/NEJMoa1509225.
[41]	Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, et al; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016; 375: 311–322. doi: 10.1056/NEJMoa1603827.
[42]	Mann JFE, Ørsted DD, Brown-Frandsen K, Marso SP, Poulter NR, Rasmussen S, Tornøe K, Zinman B, Buse JB; LEADER Steering Committee and Investigators. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med. 2017; 377: 839–848. doi: 10.1056/NEJMoa1616011.
[43]	Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, et al; SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016; 375: 1834–1844. doi: 10.1056/NEJMoa1607141.
[44]	Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, Jeppesen OK, Lingvay I, Mosenzon O, Pedersen SD, et al; PIONEER 6 Investigators. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019; 381: 841–851. doi: 10.1056/NEJMoa1901118.
[45]	Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, Chan JC, Choi J, Gustavson SM, Iqbal N, et al; EXSCEL Study Group. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017; 377: 1228–1239. doi: 10.1056/NEJMoa1612917.
[46]	Hernandez AF, Green JB, Janmohamed S, D’Agostino RB Sr, Granger CB, Jones NP, Leiter LA, Rosenberg AE, Sigmon KN, Somerville MC, et al; Harmony Outcomes committees and investigators. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomized placebo-controlled trial. Lancet. 2018; 392: 1519–1529. doi: 10.1016/S0140-6736(18)32261-X.
[47]	Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Riesmeyer JS, Riddle MC, Rydén L, et al; REWIND Investigators. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019; 394: 121–130. doi: 10.1016/S0140-6736(19)31149-3.
[48]	Gerstein HC, Sattar N, Rosenstock J, Ramasundarahettige C, Pratley R, Lopes RD, Lam CSP, Khurmi NS, Heenan L, Del Prato S, et al; AMPLITUDE-O Trial Investigators. Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. N Engl J Med. 2021; 385: 896–907. doi: 10.1056/NEJMoa2108269.
[49]	Bakris GL, Agarwal R, Anker SD, et al; FIDELIO-DKD Investigators. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020; 383: 2219-2229. [PMID: 33264825] doi: 10.1056/NEJMoa2025845.
[50]	Pitt B, Filippatos G, Agarwal R, et al; FIGARO-DKD Investigators. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021; 385: 2252-2263. [PMID: 34449181] doi: 10.1056/NEJMoa2110956.
[51]	Inker LA, Eneanya ND, Coresh J, New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race. N Engl J Med. 2021 Nov 4; 385 (19): 1737-1749. doi: 10.1056/NEJMoa2102953. Epub 2021 Sep 23.
[52]	Plantinga LC, Tuot DS, Powe NR. Awareness of chronic kidney disease among patients and providers. Adv Chronic Kidney Dis 2010 May; 17 (3): 225-236.
[53]	Greer RC, Cooper LA, Crews DC, Powe NR, Boulware LE. Quality of patient-physician discussions about CKD in primary care: a cross-sectional study. Am J Kidney Dis 2011 Apr; 57 (4): 583-591.
[54]	Ene-Iordache B, Perico N, Bikbov B, et al. Chronic kidney disease and cardiovascular risk in six regions of the world (ISN-KDDC): a cross-sectional study. Lancet Glob Health. 2016 May; 4 (5): e307-19. doi: 10.1016/S2214-109X(16)00071-1.
[55]	Finkelstein FO, Story K, Firanek C, Barre P, Takano T, Soroka S, Mujais S, Rodd K, Mendelssohn D. Perceived knowledge among patients cared for by nephrologists about chronic kidney disease and end-stage renal disease therapies. Kidney Int. 2008 Nov; 74 (9): 1178-84. doi: 10.1038/ki.2008.376. Epub 2008 Jul 30.

Cite This Article

Plain Text BibTeX RIS

APA Style

Ghnaimat, M., Ali Abu Alsamen, M., Omar Abu Hijleh, M., Jarrah, N., Al-Momani, M., et al. (2023). A Jordanian Multidisciplinary Consensus Statement on Chronic Kidney Disease Screening, Diagnosis, and Management. Journal of Family Medicine and Health Care, 9(3), 54-63. https://doi.org/10.11648/j.jfmhc.20230903.13

Copy | Download

ACS Style

Ghnaimat, M.; Ali Abu Alsamen, M.; Omar Abu Hijleh, M.; Jarrah, N.; Al-Momani, M., et al. A Jordanian Multidisciplinary Consensus Statement on Chronic Kidney Disease Screening, Diagnosis, and Management. J. Fam. Med. Health Care 2023, 9(3), 54-63. doi: 10.11648/j.jfmhc.20230903.13

Copy | Download

AMA Style

Ghnaimat M, Ali Abu Alsamen M, Omar Abu Hijleh M, Jarrah N, Al-Momani M, et al. A Jordanian Multidisciplinary Consensus Statement on Chronic Kidney Disease Screening, Diagnosis, and Management. J Fam Med Health Care. 2023;9(3):54-63. doi: 10.11648/j.jfmhc.20230903.13

Copy | Download

@article{10.11648/j.jfmhc.20230903.13,
  author = {Mohammad Ghnaimat and Muneer Ali Abu Alsamen and Mohamed Omar Abu Hijleh and Nadim Jarrah and Munther Al-Momani and Hiba Barghouthi and Abdelkarim Khawaldeh and Taroub Khoury and Riyad Said and Mazen Matalka},
  title = {A Jordanian Multidisciplinary Consensus Statement on Chronic Kidney Disease Screening, Diagnosis, and Management},
  journal = {Journal of Family Medicine and Health Care},
  volume = {9},
  number = {3},
  pages = {54-63},
  doi = {10.11648/j.jfmhc.20230903.13},
  url = {https://doi.org/10.11648/j.jfmhc.20230903.13},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.jfmhc.20230903.13},
  abstract = {Background: Chronic kidney disease (CKD) is a global public health concern, affecting millions of people worldwide and Jordan is no exception to this growing problem. CKD can be prevented or delayed through effective primary healthcare practices. However, lack of awareness among both the general population and healthcare providers (HCPs) contributes to delayed diagnosis and suboptimal management of CKD. Aims: The aims of the expert panel were to raise awareness and provide a multidisciplinary consensus approach to screening, diagnosis, and management of CKD, including identifying and controlling risk factors associated with this chronic condition. In addition, the aim was to develop treatment recommendations and algorithms to HCPs to ease the decision-making process and standardize management protocols. Methods: The multidisciplinary panel of experts from different specialties representing several medical societies met to discuss and review the challenges and barriers of CKD in Jordan. The experts also reviewed the relevant publications associated with CKD, including the outcome data trials and the international clinical practice guidelines on CKD. The multidisciplinary panel developed a comprehensive understanding of the current state of CKD in Jordan and the measures being taken to address it. Results: The multidisciplinary team of experts developed a consensus statement that is tailored to the local situation in Jordan. The panel provided standard recommendations and algorithms, addressing screening, diagnosis, referrals, and treatment of CKD. Conclusion: Early screening and interventional programs are crucial to delaying the progression nature of CKD and reducing its complications. Future follow-up is important to measure the impact of these recommendations and educational programs to HCPs on CKD detection and management and improving patients’ outcomes.
},
 year = {2023}
}

Copy | Download

TY  - JOUR
T1  - A Jordanian Multidisciplinary Consensus Statement on Chronic Kidney Disease Screening, Diagnosis, and Management
AU  - Mohammad Ghnaimat
AU  - Muneer Ali Abu Alsamen
AU  - Mohamed Omar Abu Hijleh
AU  - Nadim Jarrah
AU  - Munther Al-Momani
AU  - Hiba Barghouthi
AU  - Abdelkarim Khawaldeh
AU  - Taroub Khoury
AU  - Riyad Said
AU  - Mazen Matalka
Y1  - 2023/10/28
PY  - 2023
N1  - https://doi.org/10.11648/j.jfmhc.20230903.13
DO  - 10.11648/j.jfmhc.20230903.13
T2  - Journal of Family Medicine and Health Care
JF  - Journal of Family Medicine and Health Care
JO  - Journal of Family Medicine and Health Care
SP  - 54
EP  - 63
PB  - Science Publishing Group
SN  - 2469-8342
UR  - https://doi.org/10.11648/j.jfmhc.20230903.13
AB  - Background: Chronic kidney disease (CKD) is a global public health concern, affecting millions of people worldwide and Jordan is no exception to this growing problem. CKD can be prevented or delayed through effective primary healthcare practices. However, lack of awareness among both the general population and healthcare providers (HCPs) contributes to delayed diagnosis and suboptimal management of CKD. Aims: The aims of the expert panel were to raise awareness and provide a multidisciplinary consensus approach to screening, diagnosis, and management of CKD, including identifying and controlling risk factors associated with this chronic condition. In addition, the aim was to develop treatment recommendations and algorithms to HCPs to ease the decision-making process and standardize management protocols. Methods: The multidisciplinary panel of experts from different specialties representing several medical societies met to discuss and review the challenges and barriers of CKD in Jordan. The experts also reviewed the relevant publications associated with CKD, including the outcome data trials and the international clinical practice guidelines on CKD. The multidisciplinary panel developed a comprehensive understanding of the current state of CKD in Jordan and the measures being taken to address it. Results: The multidisciplinary team of experts developed a consensus statement that is tailored to the local situation in Jordan. The panel provided standard recommendations and algorithms, addressing screening, diagnosis, referrals, and treatment of CKD. Conclusion: Early screening and interventional programs are crucial to delaying the progression nature of CKD and reducing its complications. Future follow-up is important to measure the impact of these recommendations and educational programs to HCPs on CKD detection and management and improving patients’ outcomes.

VL  - 9
IS  - 3
ER  -

Copy | Download

Author Information

Mohammad Ghnaimat

Nephrology Private Clinic, Jordan Society of Nephrology, Renal Transplantation and the Jordanian Society of Internal Medicine, Amman, Jordan

Contact Email
Muneer Ali Abu Alsamen

General Practice Private Clinic, The Jordanian General Practitioner Society, Amman, Jordan

Contact Email
Mohamed Omar Abu Hijleh

Endocrinology, Abdali Medical Center, Amman, Jordan

Contact Email
Nadim Jarrah

Endocrinology, The Specialty Hospital, Amman, Jordan

Contact Email
Munther Al-Momani

Endocrinology Private Clinic and Al Khalidi Hospital and Medical Center, The Jordanian Society of Endocrinology, Diabetes & Metabolism, Amman, Jordan

Contact Email
Hiba Barghouthi

Nephrology, Abdali Medical Center and the Jordanian Atherosclerosis and Hypertension Society, Amman, Jordan

Contact Email
Abdelkarim Khawaldeh

Endocrinology Private Clinic, The Jordanian Society of Endocrinology, Diabetes and Metabolism, Amman, Jordan

Contact Email
Taroub Khoury

Internal Medicine Private Clinic, the Jordanian Society of Internal Medicine, and the Jordanian Atherosclerosis and Hypertension Society, Amman, Jordan

Contact Email
Riyad Said

Nephrology, Jordan Hospital, Jordan Society of Nephrology, Renal Transplantation, Amman, Jordan

Contact Email
Mazen Matalka

Clinical Research, Advanced Healthcare Solutions Contract Research Organization, Amman, Jordan

Contact Email

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Ghnaimat, M., Ali Abu Alsamen, M., Omar Abu Hijleh, M., Jarrah, N., Al-Momani, M., et al. (2023). A Jordanian Multidisciplinary Consensus Statement on Chronic Kidney Disease Screening, Diagnosis, and Management. Journal of Family Medicine and Health Care, 9(3), 54-63. https://doi.org/10.11648/j.jfmhc.20230903.13

Copy | Download

ACS Style

Ghnaimat, M.; Ali Abu Alsamen, M.; Omar Abu Hijleh, M.; Jarrah, N.; Al-Momani, M., et al. A Jordanian Multidisciplinary Consensus Statement on Chronic Kidney Disease Screening, Diagnosis, and Management. J. Fam. Med. Health Care 2023, 9(3), 54-63. doi: 10.11648/j.jfmhc.20230903.13

Copy | Download

AMA Style

Ghnaimat M, Ali Abu Alsamen M, Omar Abu Hijleh M, Jarrah N, Al-Momani M, et al. A Jordanian Multidisciplinary Consensus Statement on Chronic Kidney Disease Screening, Diagnosis, and Management. J Fam Med Health Care. 2023;9(3):54-63. doi: 10.11648/j.jfmhc.20230903.13

Copy | Download

@article{10.11648/j.jfmhc.20230903.13,
  author = {Mohammad Ghnaimat and Muneer Ali Abu Alsamen and Mohamed Omar Abu Hijleh and Nadim Jarrah and Munther Al-Momani and Hiba Barghouthi and Abdelkarim Khawaldeh and Taroub Khoury and Riyad Said and Mazen Matalka},
  title = {A Jordanian Multidisciplinary Consensus Statement on Chronic Kidney Disease Screening, Diagnosis, and Management},
  journal = {Journal of Family Medicine and Health Care},
  volume = {9},
  number = {3},
  pages = {54-63},
  doi = {10.11648/j.jfmhc.20230903.13},
  url = {https://doi.org/10.11648/j.jfmhc.20230903.13},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.jfmhc.20230903.13},
  abstract = {Background: Chronic kidney disease (CKD) is a global public health concern, affecting millions of people worldwide and Jordan is no exception to this growing problem. CKD can be prevented or delayed through effective primary healthcare practices. However, lack of awareness among both the general population and healthcare providers (HCPs) contributes to delayed diagnosis and suboptimal management of CKD. Aims: The aims of the expert panel were to raise awareness and provide a multidisciplinary consensus approach to screening, diagnosis, and management of CKD, including identifying and controlling risk factors associated with this chronic condition. In addition, the aim was to develop treatment recommendations and algorithms to HCPs to ease the decision-making process and standardize management protocols. Methods: The multidisciplinary panel of experts from different specialties representing several medical societies met to discuss and review the challenges and barriers of CKD in Jordan. The experts also reviewed the relevant publications associated with CKD, including the outcome data trials and the international clinical practice guidelines on CKD. The multidisciplinary panel developed a comprehensive understanding of the current state of CKD in Jordan and the measures being taken to address it. Results: The multidisciplinary team of experts developed a consensus statement that is tailored to the local situation in Jordan. The panel provided standard recommendations and algorithms, addressing screening, diagnosis, referrals, and treatment of CKD. Conclusion: Early screening and interventional programs are crucial to delaying the progression nature of CKD and reducing its complications. Future follow-up is important to measure the impact of these recommendations and educational programs to HCPs on CKD detection and management and improving patients’ outcomes.
},
 year = {2023}
}

Copy | Download

TY  - JOUR
T1  - A Jordanian Multidisciplinary Consensus Statement on Chronic Kidney Disease Screening, Diagnosis, and Management
AU  - Mohammad Ghnaimat
AU  - Muneer Ali Abu Alsamen
AU  - Mohamed Omar Abu Hijleh
AU  - Nadim Jarrah
AU  - Munther Al-Momani
AU  - Hiba Barghouthi
AU  - Abdelkarim Khawaldeh
AU  - Taroub Khoury
AU  - Riyad Said
AU  - Mazen Matalka
Y1  - 2023/10/28
PY  - 2023
N1  - https://doi.org/10.11648/j.jfmhc.20230903.13
DO  - 10.11648/j.jfmhc.20230903.13
T2  - Journal of Family Medicine and Health Care
JF  - Journal of Family Medicine and Health Care
JO  - Journal of Family Medicine and Health Care
SP  - 54
EP  - 63
PB  - Science Publishing Group
SN  - 2469-8342
UR  - https://doi.org/10.11648/j.jfmhc.20230903.13
AB  - Background: Chronic kidney disease (CKD) is a global public health concern, affecting millions of people worldwide and Jordan is no exception to this growing problem. CKD can be prevented or delayed through effective primary healthcare practices. However, lack of awareness among both the general population and healthcare providers (HCPs) contributes to delayed diagnosis and suboptimal management of CKD. Aims: The aims of the expert panel were to raise awareness and provide a multidisciplinary consensus approach to screening, diagnosis, and management of CKD, including identifying and controlling risk factors associated with this chronic condition. In addition, the aim was to develop treatment recommendations and algorithms to HCPs to ease the decision-making process and standardize management protocols. Methods: The multidisciplinary panel of experts from different specialties representing several medical societies met to discuss and review the challenges and barriers of CKD in Jordan. The experts also reviewed the relevant publications associated with CKD, including the outcome data trials and the international clinical practice guidelines on CKD. The multidisciplinary panel developed a comprehensive understanding of the current state of CKD in Jordan and the measures being taken to address it. Results: The multidisciplinary team of experts developed a consensus statement that is tailored to the local situation in Jordan. The panel provided standard recommendations and algorithms, addressing screening, diagnosis, referrals, and treatment of CKD. Conclusion: Early screening and interventional programs are crucial to delaying the progression nature of CKD and reducing its complications. Future follow-up is important to measure the impact of these recommendations and educational programs to HCPs on CKD detection and management and improving patients’ outcomes.

VL  - 9
IS  - 3
ER  -

Copy | Download